Clinical Trials
24
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 155
- Registration Number
- NCT05267574
- Locations
- 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺PARC Clinical Research, Adelaide, South Australia, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 213
- Registration Number
- NCT04535609
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Myology Institute, University of Florida, Gainesville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders
- Conditions
- Fatty Acid Oxidation Disorder
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 61
- Registration Number
- NCT04482049
- Locations
- 🇺🇸
Oregon Health & Science University (OHSU), Portland, Oregon, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Vanderbuilt University Medical Center, Nashville, Tennessee, United States
A Study of the Safety of REN001 in Patients With McArdle Disease
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 19
- Registration Number
- NCT04226274
- Locations
- 🇪🇸
Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
🇬🇧National Hospital for Neurology and Neurosurgery, Queens Square, London, United Kingdom
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Reneo Pharma Ltd
- Target Recruit Count
- 23
- Registration Number
- NCT03862846
- Locations
- 🇬🇧
Institute of Neurology, University College London, London, United Kingdom
🇬🇧Wellcome Centre for Mitochondrial Research, Newcastle Upon Tyne, United Kingdom
- Prev
- 1
- 2
- Next